Thalassemia Related Iron Overload Therapeutics

1. Ferriprox patent expiration

Treatment: Method of treating transfusional iron overload

FERRIPROX IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7049328 CHIESI Use for deferiprone
Jun, 2021

(4 years ago)

US11723874 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(12 years from now)

US8703156 CHIESI Liquid formulation for deferiprone with palatable taste
Oct, 2029

(3 years from now)

US11357731 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(12 years from now)

US10940115 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(12 years from now)

US10780055 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(12 years from now)

US11458103 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(12 years from now)

US10940116 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 14, 2016
Orphan Drug Exclusivity(ODE) Oct 14, 2018
Orphan Drug Exclusivity(ODE-16) Oct 14, 2018
New Indication(I-859) Apr 30, 2024
Orphan Drug Exclusivity(ODE-417) Apr 30, 2028
Orphan Drug Exclusivity(ODE-418) Apr 30, 2028
Orphan Drug Exclusivity(ODE-419) Apr 30, 2028
Orphan Drug Exclusivity(ODE-420) Apr 30, 2028
Orphan Drug Exclusivity(ODE-421) Apr 30, 2028

Drugs and Companies using DEFERIPRONE ingredient

NCE-1 date: 15 October, 2015

Market Authorisation Date: 25 July, 2019

Dosage: TABLET; SOLUTION

How can I launch a generic of FERRIPROX before it's drug patent expiration?
More Information on Dosage

FERRIPROX family patents

Family Patents